Advances in our understanding of thyroid cancer biology have led to the regulatory approval of a number of molecularly targeted therapies for advanced-stage disease. Herein, the authors summarize the progress made to date in molecular medicine for the different histotypes of thyroid cancer, and highlight the questions for future research focused on treatment of the various disease subtypes.
- Keith C. Bible
- Mabel Ryder
